Callitas Health, Inc. Announces Corporate Update

Author's Avatar
Apr 12, 2019
Article's Main Image

CINCINNATI, OH / ACCESSWIRE / September 18, 2018 / Callitas Health Inc. (CNSX: LILY, OTCQB: MPHMF, FSE: T3F3), (the "Company" or "Callitas"), an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, today announced that it has been notified by the British Columbia Securities Commission of regulatory deficiencies for the second quarter ended June 30, 2018. A cease trade order was issued for failure to file the second quarter financial statements and report, as well as the management disccussion and analysis prior to August 30, 2018.